Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.37 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.37 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16905841 | 0.87 | L3MBTL1 (0.53) | L3MBTL1USP2KDM4ESLC5A1SLC5A2 | |
| SCHEMBL16905970 | 0.87 | TP53 (0.47) | L3MBTL1PDE4BHTR2AHTR2CPOLB | |
| SCHEMBL20373558 | 0.86 | L3MBTL1 (0.52) | L3MBTL1BRD4HTR2AHTR2CPOLB | |
| SCHEMBL16905973 | 0.83 | L3MBTL1 (0.46) | L3MBTL1HTR2CPOLBMAPTRXFP1 | |
| SCHEMBL18326362 | 0.83 | L3MBTL1 (0.46) | L3MBTL1BRD4HTR2CPOLBMAPT | |
| SCHEMBL16896893 | 0.82 | BRD4 (0.44) | L3MBTL1BRD4PDE4B | |
| SCHEMBL16905984 | 0.81 | BRD4 (0.54) | L3MBTL1BRD4HTR2AHTR2CMAPT | |
| SCHEMBL31457804 | 0.80 | L3MBTL1 (0.40) | L3MBTL1HTR2APOLBMAPTRXFP1 | |
| SCHEMBL26654846 | 0.80 | L3MBTL1 (0.40) | L3MBTL1HTR2APOLBMAPTRXFP1 | |
| SCHEMBL20373748 | 0.80 | L3MBTL1 (0.41) | L3MBTL1BRD4POLBMAPTRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590118-B2 | Bicyclic heterocyclic derivatives as bromodomain inhibitors | ORION CORPORATION (FI) | 2020-03-17 | — | — | US | disclosed |
| US-10590118-B2 | Bicyclic heterocyclic derivatives as bromodomain inhibitors | ORION CORPORATION (FI) | 2020-03-17 | — | — | US | disclosed |
| US-20180339982-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2018-11-29 | — | — | US | disclosed |
| US-10077259-B2 | Bicyclic heterocyclic derivatives as bromodomain inhibitors | ORION CORPORATION (FI) | 2018-09-18 | — | — | US | disclosed |
| EP-3092227-B1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORP (FI) | 2018-07-11 | — | — | EP | disclosed |
| EP-3092227-B1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORP (FI) | 2018-07-11 | — | — | EP | disclosed |
| US-20160368906-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2016-12-22 | — | — | US | disclosed |
| US-20160368906-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2016-12-22 | — | — | US | disclosed |
| US-20160368906-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2016-12-22 | — | — | US | disclosed |
| WO-2015104653-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368906-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD1, BRD2, BRD3 | L3MBTL1 2541/4885BRD4 4/4885PDE4B 1031/4885 |
| US-20180339982-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD1, BRD2, BRD3 | L3MBTL1 2541/4885BRD4 4/4885PDE4B 1031/4885 |
| US-10590118-B2 | Bicyclic heterocyclic derivatives as bromodomain inhibitors | BRD1, BRD2, BRD3 | L3MBTL1 2541/4885BRD4 4/4885PDE4B 1031/4885 |
| US-10077259-B2 | Bicyclic heterocyclic derivatives as bromodomain inhibitors | BRD1, BRD2, BRD3 | L3MBTL1 2541/4885BRD4 4/4885PDE4B 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.